1496 PUBLICATION Phase 1 study to determine tolerability and pharmacokinetics (PK) of D0/NDR/02, a novel nanoparticle paclitaxel in patients with locally advanced or metastatic breast cancer (MBC)

Phase 1 ◽

Locally Advanced ◽

Metastatic Breast ◽

Abstract PD8-07: Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

10.1158/1538-7445.sabcs20-pd8-07 ◽

2021 ◽

Author(s):

Philippe Aftimos ◽

Marina Maglakelidze ◽

Andor WJM Glaudemans ◽

Erika Hamilton ◽

Linnea Chap ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase 1 ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 1 Study ◽

Pharmacodynamic Analysis

Abstract P2-16-10: Combination of Tivozanib, an Oral Inhibitor of VEGFR, with Weekly Paclitaxel for Metastatic Breast Cancer: Preliminary Results of an Ongoing Phase 1 Study

10.1158/0008-5472.sabcs10-p2-16-10 ◽

2010 ◽

Author(s):

EL Mayer ◽

M Scheulen ◽

J Beckman ◽

H Richly ◽

A Poli ◽

...

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Phase 1 Study ◽

Preliminary Results ◽

Ongoing Phase

Abstract OT3-02-14: A phase 1 study in patients with metastatic breast cancer to evaluate the feasibility of magnetic resonance imaging with ferrumoxytol as a potential biomarker for response to treatment with nanoliposomal irinotecan (nal-IRI, MM-398)

10.1158/1538-7445.sabcs15-ot3-02-14 ◽

2016 ◽

Author(s):

JC Sachdev ◽

RK Ramanathan ◽

N Raghunand ◽

C Anders ◽

P Munster ◽

...

Keyword(s):

Breast Cancer ◽

Magnetic Resonance Imaging ◽

Phase 1 ◽

Metastatic Breast ◽

Response To Treatment ◽

Resonance Imaging ◽

Phase 1 Study ◽

Potential Biomarker ◽

Nanoliposomal Irinotecan

Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer

10.1158/1538-7445.sabcs17-pd3-14 ◽

2018 ◽

Cited By ~ 2

Author(s):

S Modi ◽

L Pusztai ◽

A Forero ◽

M Mita ◽

KD Miller ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Metastatic Breast ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Drug Conjugate ◽

Heavily Pretreated ◽

Antibody Drug

Abstract P4-15-09: Phase 1 study of trastuzumab emtansine in HER2-positive metastatic breast cancer patients with normal or reduced hepatic function

10.1158/1538-7445.sabcs14-p4-15-09 ◽

2015 ◽

Author(s):

Chunze Li ◽

Priya Agarwal ◽

Susan Dent ◽

Anthony Goncalves ◽

Joo-Hee Yi ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase 1 ◽

Metastatic Breast ◽

Hepatic Function ◽

Trastuzumab Emtansine ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer

10.1158/1538-7445.sabcs16-p6-12-04 ◽

2017 ◽

Author(s):

A Forero-Torres ◽

S Modi ◽

J Specht ◽

K Miller ◽

A Weise ◽

...

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Metastatic Breast ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Drug Conjugate ◽

Heavily Pretreated ◽

Antibody Drug

Phase 1 study of triweekly nab-paclitaxel combined with S-1 in patients with HER2 negative metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e12510 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e12510-e12510

Author(s):

Katsuhiko Nakatsukasa ◽

Tetsuya Taguchi ◽

Kouichi Sakaguchi ◽

Yoshihumi Hujita

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Metastatic Breast ◽

A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2021.08.003 ◽

2021 ◽

Author(s):

Patricia LoRusso ◽

Erika Hamilton ◽

Cynthia Ma ◽

Neelima Vidula ◽

Rebecca G. Bagley ◽

...

Keyword(s):

Breast Cancer ◽

Androgen Receptor ◽

Phase 1 ◽

Metastatic Breast ◽

Selective Androgen Receptor Modulator ◽

Phase 1 Study ◽

Receptor Modulator

Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps1108 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS1108-TPS1108 ◽

Author(s):

Ruth O'Regan ◽

Randolph Hurley ◽

Jasgit C. Sachdev ◽

Debra A. Tonetti ◽

Gregory R. Thatcher ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Phase 1 ◽

Metastatic Breast ◽

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer

Cancer ◽

10.1002/cncr.26571 ◽

2011 ◽

Vol 118 (9) ◽

pp. 2378-2384 ◽

Cited By ~ 16

Author(s):

Stacy Moulder ◽

Gregory Gladish ◽

Joe Ensor ◽

Ana Maria Gonzalez-Angulo ◽

Massimo Cristofanilli ◽

...

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Metastatic Breast ◽